Trade Report: Today, Brokerages Set Intra-Cellular Therapies Inc. (ITCI) PT at $39.83

Today, Brokerages Set Intra-Cellular Therapies Inc. (ITCI) PT at $39.83

Shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) have been assigned an average recommendation of “Hold” from the nine analysts that are covering the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $39.83.

A number of research analysts recently weighed in on ITCI shares. Leerink Swann reaffirmed a “buy” rating and set a $95.00 price objective on shares of Intra-Cellular Therapies in a report on Thursday, August 11th. Cowen and Company reaffirmed a “buy” rating and set a $75.00 price objective on shares of Intra-Cellular Therapies in a report on Friday, August 5th. Piper Jaffray Cos. set a $22.00 price objective on Intra-Cellular Therapies and gave the stock a “buy” rating in a report on Monday, October 10th. Zacks Investment Research raised Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a report on Friday, November 11th. Finally, JMP Securities lowered Intra-Cellular Therapies from an “outperform” rating to a “market perform” rating in a report on Thursday, September 29th.

In related news, Director Christopher D. Alafi acquired 34,000 shares of Intra-Cellular Therapies stock in a transaction dated Monday, November 14th. The shares were acquired at an average cost of $14.50 per share, for a total transaction of $493,000.00. Following the completion of the transaction, the director now directly owns 730,529 shares of the company’s stock, valued at $10,592,670.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 19.80% of the stock is owned by insiders.

Several hedge funds have recently modified their holdings of ITCI. Royal Bank of Canada increased its stake in shares of Intra-Cellular Therapies by 23.1% in the second quarter. Royal Bank of Canada now owns 2,684 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 504 shares in the last quarter. Bank of Montreal Can bought a new stake in shares of Intra-Cellular Therapies during the second quarter valued at about $155,000. Mycio Wealth Partners LLC increased its stake in shares of Intra-Cellular Therapies by 14.3% in the second quarter. Mycio Wealth Partners LLC now owns 4,398 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 550 shares in the last quarter. Teacher Retirement System of Texas increased its stake in shares of Intra-Cellular Therapies by 13.7% in the second quarter. Teacher Retirement System of Texas now owns 4,532 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 546 shares in the last quarter. Finally, Legal & General Group Plc increased its stake in shares of Intra-Cellular Therapies by 29.3% in the second quarter. Legal & General Group Plc now owns 5,282 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 1,197 shares in the last quarter. Institutional investors and hedge funds own 67.13% of the company’s stock.

Shares of Intra-Cellular Therapies (NASDAQ:ITCI) opened at 13.58 on Tuesday. The firm’s market capitalization is $587.58 million. Intra-Cellular Therapies has a 12 month low of $10.80 and a 12 month high of $59.96. The company’s 50 day moving average price is $13.31 and its 200-day moving average price is $32.19.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.84) by $0.14. The business had revenue of $4.36 million for the quarter, compared to analyst estimates of $0.04 million. During the same period in the prior year, the company earned ($0.91) EPS. The company’s revenue was up NaN% on a year-over-year basis. On average, equities analysts predict that Intra-Cellular Therapies will post ($2.84) earnings per share for the current fiscal year.

Related posts

Leave a Comment